Detailed Safety Review of
Anthrax Vaccine Adsorbed – January 2012.
Compiled by the Military Vaccine (MILVAX)
Link to report
– updated July 2012 [link].
1) reducing the number of doses required to complete the
pre-event and preexposure primary series from 6 doses to
2) recommending intramuscular rather than subcutaneous
AVA administration for preexposure use,
3) recommending AVA as a component of postexposure
prophylaxis in pregnant women exposed to aerosolized
Bacillus anthracis spores,
4) providing guidance regarding preexposure vaccination
of emergency and other responder organizations under the
direction of an occupational health program, and
5) recommending 60 days of antimicrobial prophylaxis in
conjunction with 3 doses of AVA for optimal protection
of previously unvaccinated persons after exposure to
aerosolized B. anthracis spores.
CDC’s Vaccine Information
Statement (VIS) updated March 2010 [link]
Stewart B, et al.
Health-related quality of life in the CDC
Anthrax Vaccine Adsorbed Human Clinical Trial.
A study of more than 1500 participants
found no association between receipt of Anthrax Vaccine
and altered health-related quality of life over 3.5
Murphy D, et al.
A longitudinal study of UK military personnel
offered anthrax vaccination: informed choice, symptom
reporting, uptake and pre-vaccination health.
UK service personnel were followed for
3-6 years after anthrax vaccination to assess long term
health. Anthrax vaccination was not associated with
long term adverse health problems. However, symptoms
were associated with making an uninformed choice to
undergo the vaccination. The results are important both
for the safety of the vaccine and for future policies
should anthrax vaccination be required in either
military or non military populations.
US Department of Defense
announced the continuation
of the anthrax and smallpox vaccination programs. The
programs will be expanded to also include units in the
Pacific region, the Middle East and South Korea. Dr.
William Winkenwerder, assistant secretary of defense for
health affairs, indicated that these changes were the
result of availability of additional smallpox and
anthrax vaccine - not an increased risk of of biological
warfare in those regions. (June 30, 2004)
The Anthrax Vaccine: Is It Safe● Does It Work●
reports the study’s conclusion that the vaccine is
acceptably safe and effective in protecting humans
against anthrax. The book also includes a description of
advances needed in main areas: improving the way the
vaccine is now used, expanding surveillance efforts to
detect side effects from its use, and developing a
better vaccine. (March
Center for Biosecurity at the
University of Pittsburgh Medical Center -
As of November 1,
2003, the faculty and staff formerly of the
Johns Hopkins Center for Civilian Biodefense Strategies
are now affiliated with the Center for
Biosecurity of the University of Pittsburgh Medical
Centers for Disease Control and
U.S. Department of
World Health Organization